Knight Therapeutics Inc. (GUD:CA) Rises 13.85% for October 21

Equities Staff  |

October 21 was a positive day for Knight Therapeutics Inc. (GUD:CA) as its stock finished the day having gained 13.85% to hit a price of $8.55 a share. The company reached a market cap of 1.18 billion and has 135.96 million shares outstanding. Knight Therapeutics Inc. is a component of the the S&P/TSX SmallCap Index.

1.12 million shares changed hands over the course of the day as compared to an average volume of n/a over the last 30 days for Knight Therapeutics Inc..

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.. The company makes its home in Montreal, QC, and is currently under the leadership of CEO Jonathan Ross Goodman.

Knight Therapeutics Inc. has hit a high of $8.69 and reached a low of $7.10 over its last year of trading. The stock’s 50-day SMA is now $n/a and 200-day SMA is $n/a. As for its price valuations, the P/E ratio is at n/a and P/B is now 1.13.

Still paying commissions on stock trades? Equities.com now offers $7.99/month unlimited trading and flat-fee options trading for $89.99/month! Get started today by https://www.equities.com/trading-start

The S&P/TSX SmallCap Index tracks over 200 Canadian small-cap stocks for cumulative performance. Relying on market cap weighting to calculate returns, it’s an index similar in composition to the Russell 2000, only focused on Canadian companies and much smaller in terms of its total membership. Widely recognized as the benchmark for small-cap Canadian stocks, the member companies must have a market cap between C$100 million and C$1.5 billion and an average share price of at least C$1.

To get more information on Knight Therapeutics Inc. and to follow the company’s latest updates, you can visit the company’s profile page here: GUD:CA’s Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.com’s Newsdesk. Also, don’t forget to sign-up for our daily email newsletter to ensure you don’t miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.



DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Watchlist

Symbol Last Price Change % Change
AAPL

     
AMZN

     
HD

     
JPM

     
IBM

     
BA

     
WMT

     
DIS

     
GOOG

     
XOM

     
BRK.A

     
FB

     
JNJ

     
WFC

     
T

     
NFLX

     
TSLA

     
V

     
UNH

     
PG

     

World Economic Forum at Davos 2019 - Ben Yablon Executive VP Salt Lending

Matt Bird sits down with Ben Yablon - Executive VP of Salt Lending - at the World Economic Forum in Davos January 2019